Health care and biotech companies have had some big moves over the past year, but seem to be settling back into the relative underperformance that marked the pre-pandemic era. That’s also applied to pharmaceutical companies too, including those who have developed Covid vaccines. The drug industry’s historically rapid development of a vaccine seems to be no longer impressive. Neither does the likely profits to be had thanks to government support and backing. Case in point?Pfizer (PFE). Shares have shed more than 20 percent from a peak in early December, marking a bear market. Other bi...
More








